Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
CMMB Stock Chart & Stats
$1.89
-$0.02(-0.88%)
At close: 4:00 PM EST
$1.89
-$0.02(-0.88%)
Day’s Range― - ―
52-Week Range$2.36 - $9.84
Previous CloseN/A
Volume58.22K
Average Volume (3M)207.96K
Market Cap
$11.63M
Enterprise Value$9.28M
Total Cash (Recent Filing)$10.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 11, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding6,155,117
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-275.40
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$25.00Price Target Upside1222.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignFavorable regulatory feedback enables a streamlined pivotal program, positioning Chemomab for a more efficient and lower-cost pivotal study.
Drug MechanismChemomab's CM-101 is differentiated from other drugs due to its dual-acting mechanism on inflammation and fibrosis.
Regulatory ApprovalChemomab has received positive feedback from the FDA, which supports the advancement of Nebokitug into Phase 3 for primary sclerosing cholangitis.
Bears Say
Enrollment ComplicationsAvoiding a biopsy endpoint was a key objective of Chemomab's regulatory interactions. Biopsy endpoints complicate enrollment and add considerable additional cost.
Study ComplexityThe lack of a required confirmatory keeps timelines on track and reduces the overall cost.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $2.36 and its highest was $9.84 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $11.63M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 77 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Nov 20, 2025. The company reported -$0.016 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.024.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is -0.04.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 6,155,117 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.016 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics (CMMB) is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for the treatment of inflammatory and fibrotic diseases. The company's core product is CM-101, a monoclonal antibody designed to address key pathways involved in fibrosis and inflammation, offering potential treatments for conditions such as primary sclerosing cholangitis (PSC), systemic sclerosis, and liver fibrosis.
CMMB Stock 12 Month Forecast
Average Price Target
$25.00
▲(1222.75% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
5.06% Other Institutional Investors
94.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---